Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Oct;71(1):39-44.
doi: 10.1016/s0020-7292(00)00254-x.

beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence

O Ishiko  1 , T Ushiroyama, F Saji, Y Mitsuhashi, T Tamura, K Yamamoto, Y Kawamura, S Ogita
Affiliations
Clinical Trial

beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence

O Ishiko et al. Int J Gynaecol Obstet. 2000 Oct.

Abstract

Objective: We compared beta(2)-adrenergic agonist therapy with clenbuterol (DT) and physiological therapy (PT) in a randomized study to establish the first line therapy for stress incontinence (SI).

Method: The clinical efficacy of DT (group A), PT (group B), and a combination of DT and PT (group C) was investigated in 61 patients with SI by means of a 12-week randomized controlled study. The frequency and volume of SI and the patients' own impressions were used as the basis for the assessment of efficacy.

Results: The SI improvement rates in groups A, B, and C were 76.9, 52.6, and 89. 5%, respectively (P=0.0361). A significant therapeutic effect on the frequency of SI was observed in group B and group C at 2 weeks after the start of treatment (both P<0.05), and in all groups at 6 weeks (all P<0.01). The efficacy rates based on the patients' own impressions in groups A, B, and C were 84.6, 31.6, and 68.4%, respectively (P=0.0064).

Conclusion: The beta(2)-adrenergic agonist appeared to be clinically useful as a drug of choice for SI.

PubMed Disclaimer

LinkOut - more resources